Skip to search formSkip to main contentSkip to account menu
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 *
TLDR
The Zar Review Group: I.J. Bousquet, N. Khaltaev, A. R. Rabe, J. Rosado-Pinto, G. Scadding, F. Simons, E. Togias, T. Valovirta, P. Vandenplas, D. Wang, M. Stoloff, O. Williams.
View on Wiley
Asthma. From bronchoconstriction to airways inflammation and remodeling.
TLDR
This work has shown that chronic inflammation in the different forms of Asthma can affect both the severity and duration of the symptoms of the disease and the treatment options for these conditions vary greatly.
View on PubMed
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program.
TLDR
Five distinct clinical phenotypes of asthma have been identified using an unsupervised hierarchical cluster analysis, which supports clinical heterogeneity in asthma and the need for new approaches for the classification of disease severity in asthma.
View on PubMed
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.
TLDR
New definitions for asthma control, severity, and exacerbations are developed, based on current treatment principles and clinical and research relevance, to provide a basis for a multicomponent assessment of asthma by clinicians, researchers, and other relevant groups in the design, conduct, and evaluation of clinical trials, and in clinical practice.
View on PubMed
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
TLDR
The addition of omalizumab to standard asthma therapy reduces asthma exacerbations and decreases inhaled corticosteroid and rescue medication use.
View on PubMed
Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma
TLDR
Patients who received dupilumab had significantly lower rates of severe asthma exacerbation than those who received placebo, as well as better lung function and asthma control.
View on Wolters Kluwer
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind,…
View on Elsevier
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
TLDR
A 1-year, randomized, stratified, double-blind, parallel-group study of 3,421 patients with uncontrolled asthma, confirming that the goal of guideline-derived asthma control was achieved in a majority of the patients.
View on PubMed
Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
TLDR
The difference in exacerbation frequency between omalizumab and placebo was greatest in the three high-biomarker subgroups, probably associated with the greater risk for exacerbations in high subgroups.
View on PubMed
Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License